JHU TRAC: Training and Supporting the Next Generation of TB Researchers

JHU TRAC：培训和支持下一代结核病研究人员

• 批准号: 10431020
• 负责人: Richard E. Chaisson
• 金额: $ 99.66万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-03-16 至 2027-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10431020
• 关键词: Address; Animal Model; Area; Baltimore; Basic Science; Bioinformatics; Biological Assay; Biometry; Biostatistics Core; Cessation of life; Clinical; Clinical Pharmacology; Clinical Research; Clinical Sciences; Clinical Trials; Collaborations; Communities; Computer Models; Cost Effectiveness Analysis; Country; Data; Development; Diagnosis; Diagnostic; Discipline; Disease; Economic Models; Education and Outreach; Effectiveness; Engineering; Ensure; Epidemic; Epidemiology; Funding; Generations; Goals; Government; HIV; Health; Health Services Accessibility; Image; Immunology; In Vitro; Interdisciplinary Study; Intervention; Knowledge; Laboratories; Mentors; Microbiology; Mission; Modeling; Mycobacterium tuberculosis; Output; Participant; Pathogenesis; Pharmaceutical Preparations; Pharmacology; Pharmacology Study; Policies; Population Dynamics; Prevention; Productivity; Protocols documentation; Public Health Nursing; Research; Research Personnel; Role; Sampling; Scientist; Services; Site; Specific qualifier value; Strategic Planning; Sum; Talents; Training; Training Programs; Training Support; Translational Research; Tuberculosis; Underrepresented Populations; United States National Institutes of Health; Universities; World Health Organization; animal imaging; base; biosafety level 3 facility; career; clinical research site; design; diagnostic tool; drug development; efficacy validation; epidemiological model; evidence base; experience; global health; imaging facilities; improved; innovation; interdisciplinary collaboration; large datasets; mathematical model; medical schools; meetings; member; microbial; multidisciplinary; next generation; novel; novel diagnostics; pandemic disease; pharmacokinetics and pharmacodynamics; pharmacometrics; pre-clinical; public health intervention; radiotracer; recruit; research study; symposium; synergism; tool; training opportunity; translational model; tuberculosis treatment

ABSTRACT — JHU TRAC OVERALL Tuberculosis (TB) remains a major global health problem, and advances in the basic and clinical sciences are urgently needed to make progress towards the World Health Organization’s End TB Strategy goal of reducing TB deaths by 95% and new cases by 90% between 2015 and 2035. The Johns Hopkins University (JHU) Center for Tuberculosis Research (CTR) has been a global leader in TB pathogenesis, translational models, diagnostics, drug development, pharmacology, public health interventions, and epidemiological and economic modeling for more than two decades. Research emanating from the CTR and JHU has transformed the treatment of TB infection and disease, elucidated interactions between TB and HIV drugs, validated the efficacy and effectiveness of new diagnostic tools, and contributed to the development of evidence-based policies for global TB control, based on the epidemiology and population dynamics of TB. However, to make further progress in efforts to achieve the END TB goals, additional innovative, cross-disciplinary and impactful research is critical and a new generation of TB scientists must be recruited and trained, particularly among groups nationally underrepresented in health-related research (UHRR). We have assembled a multidisciplinary team of researchers from multiple departments spanning four JHU schools (Medicine, Public Health, Nursing and Engineering), with complementary expertise in microbial pathogenesis, immunology, animal models, imaging, clinical trials, diagnostics, epidemiology, pharmacology and pharmacometrics, computational modeling, and biostatistics, in order to provide added value to the TB research enterprise at JHU optimize training opportunities for junior investigators and support for new, interdisciplinary collaborations, with the goal of addressing key knowledge gaps in TB research. The JHU TRAC team comprises 58 researchers, including 32 experienced TB researchers (19 current members of the CTR), 15 senior researchers new to the TB field, and 11 Early Stage Investigators (ESI). The overarching mission of the JHU TRAC is to advance TB research by promoting innovative, multidisciplinary collaborations and by recruiting, training and supporting junior Investigators, especially among UHRR groups, to develop the next generation of leaders in TB research. To this end, the JHU TRAC will focus on these four areas: 1) Enhance the integration, productivity and impact of JHU TB research; 2) Provide mentoring, support, and pilot funding for the next generation of TB researchers, and to increase the pipeline of junior investigators from UHRR groups; 3) Support TB researchers with direct services from a Clinical Core and three Scientific Cores; 4) Contribute to the END TB goals through global engagement, training, outreach, and collaboration with partners in high-burden countries. The JHU TRAC is organized into six Cores (Adminsitrative Core (AC); Developmental Core (DC); Clinical Core (CC); Microbiology, Immunology, Animal Modeling and Imaging (MIAMI) Core; Pharmacology and Pharmacometrics Core (PPC); and Bioinformatics, Modeling and Biostatistics Core (BMBC), which will interact closely with each other to promote synergy in TB research, and ensure that the utility and output of the JHU TRAC is greater than the sum of its parts.

摘要- JHU TRAC概述 结核病（TB）仍然是一个主要的全球健康问题，基础和临床科学的进步正在推动 迫切需要在实现世界卫生组织终止结核病战略减少结核病的目标方面取得进展 在2015年至2035年期间，死亡人数减少95%，新病例减少90%。约翰·霍普金斯大学（JHU）中心 结核病研究（CTR）一直是结核病发病机制，转化模型，诊断，药物治疗和治疗方面的全球领导者。 发展，药理学，公共卫生干预措施，流行病学和经济建模， 二十年CTR和JHU的研究改变了结核病感染的治疗， 疾病，阐明了结核病和艾滋病毒药物之间的相互作用，验证了新的 诊断工具，并为制定全球结核病控制循证政策做出了贡献， 结核病的流行病学和人口动态。然而，为了在努力实现结核病最终目标方面取得进一步进展， 为了实现这些目标，额外的创新性、跨学科和有影响力的研究至关重要， 必须招募和培训科学家，特别是在全国卫生相关领域代表性不足的群体中。 研究（UHRR）。我们已经组建了一个多学科的研究团队，来自多个部门， 四所JHU学校（医学，公共卫生，护理和工程），在微生物领域具有互补的专业知识 发病机理、免疫学、动物模型、成像、临床试验、诊断学、流行病学、药理学和 药物计量学、计算建模和生物统计学，以便为结核病研究提供附加值 企业在JHU优化初级研究人员的培训机会，并支持新的，跨学科的 合作，目标是解决结核病研究中的关键知识差距。JHU TRAC团队包括 58名研究人员，包括32名经验丰富的结核病研究人员（19名现任CTR成员），15名高级研究人员 新的结核病领域，和11个早期阶段的研究人员（ESI）。JHU TRAC的首要使命是推进 通过促进创新的、多学科的合作以及通过招募、培训和支持 初级研究人员，特别是UHRR小组中的初级研究人员，以培养结核病研究的下一代领导人。到 为此，JHU TRAC将重点关注以下四个领域：1）加强JHU的一体化、生产力和影响力 结核病研究; 2）为下一代结核病研究人员提供指导、支持和试点资金， 增加来自UHRR小组的初级研究人员的管道; 3）通过以下直接服务支持结核病研究人员： 一个临床核心和三个科学核心; 4）通过全球参与、培训、 外联以及与高负担国家的伙伴合作。JHU TRAC分为六个核心 （管理核心（AC）;发展核心（DC）;临床核心（CC）;微生物学、免疫学、动物 建模和成像（迈阿密）核心;药理学和药物计量学核心（PPC）;和生物信息学， 建模和生物统计学核心（BMBC），它们将相互密切互动，以促进结核病的协同作用 （c）开展研究，并确保JHU TRAC的效用和产出大于其各部分之和。